|
Volumn 137, Issue 11, 2017, Pages 2443-2444
|
HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients
|
Author keywords
[No Author keywords available]
|
Indexed keywords
HLA A ANTIGEN;
HLA A26 ANTIGEN;
NIVOLUMAB;
UNCLASSIFIED DRUG;
IMMUNOLOGICAL ANTINEOPLASTIC AGENT;
ADULT;
AGED;
ALLELE;
ARTICLE;
CANCER IMMUNOTHERAPY;
CANCER PATIENT;
CLINICAL OUTCOME;
COHORT ANALYSIS;
DRUG EFFICACY;
DRUG RESPONSE;
FEMALE;
GENE FREQUENCY;
HLA TYPING;
HUMAN;
JAPANESE (PEOPLE);
MAJOR CLINICAL STUDY;
MALE;
MELANOMA;
PREDICTIVE VALUE;
PRIORITY JOURNAL;
ETHNOLOGY;
GENETICS;
JAPAN;
MIDDLE AGED;
MOLECULARLY TARGETED THERAPY;
MORTALITY;
PATHOLOGY;
PROCEDURES;
RETROSPECTIVE STUDY;
RISK ASSESSMENT;
SKIN TUMOR;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
VERY ELDERLY;
ADULT;
AGED;
AGED, 80 AND OVER;
ALLELES;
ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL;
COHORT STUDIES;
FEMALE;
HLA-A ANTIGENS;
HUMANS;
JAPAN;
MALE;
MELANOMA;
MIDDLE AGED;
MOLECULAR TARGETED THERAPY;
NIVOLUMAB;
RETROSPECTIVE STUDIES;
RISK ASSESSMENT;
SKIN NEOPLASMS;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
EID: 85032033605
PISSN: 0022202X
EISSN: 15231747
Source Type: Journal
DOI: 10.1016/j.jid.2017.06.023 Document Type: Article |
Times cited : (10)
|
References (6)
|